舒洛地特联合薄芝糖肽对早期糖尿病肾病患者尿白蛋白排泄率的影响  

Effects of sulodexide combined with bozhi glycopeptide on urinary albumin excretion rates in patients with early diabetic nephropathy

作　　者：谢锐[1] 刘志康[1] 李列平[1] 廖志敏[1] 万波[1] 吴刚[1] 张璐璐[1] 王利平[1] 

机构地区：[1]凉山州第二人民医院,四川西昌615000

出　　处：《中国新药与临床杂志》2016年第11期821-824,共4页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：目的比较舒洛地特单用或与薄芝糖肽合用对早期糖尿病肾病患者尿白蛋白排泄率(UAER)的影响。方法早期糖尿病肾病患者86例,随机分为两组,每组43例。在常规治疗的基础上,对照组给予舒洛地特注射液2 m L,肌内注射,qd,连续15 d后改口服,舒洛地特软胶囊1粒,po,bid,连续35 d。观察组在对照组治疗基础上加用薄芝片,3片,po,tid,连续50 d。两组均为每4个月治疗1次,1年3次。观察两组患者UAER、血清胱抑素C(CysC)水平和糖尿病肾病进展,记录不良反应发生情况。结果对照组完成41例,观察组完成40例。治疗后观察组UAER、CysC降低(29.81±10.47)μg·min^(-1)、(0.71±0.57)mg·L^(-1),对照组降低(15.91±10.78)μg·min^(-1)、(0.58±0.36)mg·L^(-1),与治疗前比较均有显著差异(P<0.05),且观察组下降幅度大于对照组(P<0.05)。观察组糖尿病肾病分期情况优于对照组(P<0.05),两组均无严重不良反应发生。结论舒洛地特联合薄芝糖肽可降低早期糖尿病肾病患者UAER,并在一定程度上延缓糖尿病肾病进展。AIM To compare the effect of sulodexide alone or combined with bozhi glycopeptide on urinary albumin excretion rates （UAER） of early diabetic nephropathy patients. METHODS Eighty-six patients with early diabetic nephropathy were randomly divided into control group and observation group, 43 cases in each group. On the basis of routine treatment, the control group was given sulodexide injection （2 mL, im, qd）, which changed to sulodexide soft capsule 15 days later （1 grain, po, bid, for 35 days）. The observation group was given bozi tablet （3 tablets, po, tid, for 50 days） besides the aforesaid therapy. Both groups were treated 1 time every 4 months, and 3 courses in 1 year. The levels of UAER and serum cystatin C （CysC） before and after the treatment, progression of diabetic nephropathy, and the incidence of adverse reaction in both groups were observed. RESULTS Forty-one patients in the control group and 40 patients in the observation group completed the study. After the treatment, the levels of UAER and CysC in both groups were significantly lower than those pre-therapy （P 〈 0.05）. The levels of UAER and CysC were decreased （29.81 ± 10.47） μg· min-1 and （0.71 μ 0.57） mg·L-1 in the observation group, while （15.91 ± 10.78） μg·min-1 and （0.58 ± 0.36） mg·L-1 in the control group. The descend ranges were more predominance in the observation group compared with the control group （P 〈 0.05）. The diabetic nephropathy staging of the observation group was better than that of the control group （P 〈 0.05）. No obvious adverse reactions occurred in both groups. CONCLUSION Sulodexide combined with bozhi glycopeptide can reduce UAER in patients with early diabetic nephropathy, and delay the progression of diabetic nephropathy in partly.

关 键 词：舒洛地特 薄芝糖肽 糖尿病肾病 尿白蛋白排泄率 

分 类 号：R971[医药卫生—药品]